Kidney involvement in systemic sclerosis

Presse Medicale

Volumn 43, Issue 10, 2014, Pages e305-e314

  Steen, Virginia D ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CAPTOPRIL; COCAINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; KIDNEY RENIN; PREDNISONE; RNA ANTIBODY; RNA POLYMERASE III ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AGE; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; EARLY DIAGNOSIS; GENDER; HEMODIALYSIS; HUMAN; HYPERRENINEMIA; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LABORATORY DIAGNOSIS; MALIGNANT HYPERTENSION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PREDICTION; PROGNOSIS; RHEUMATIC DISEASE; RISK FACTOR; SCLERODERMA RENAL CRISIS; SHORT SURVEY; SURVIVAL RATE; SYSTEMIC SCLEROSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA; COMPLICATION; KIDNEY DISEASES;

HUMANS; KIDNEY DISEASES; PROGNOSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84908462840     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.02.031     Document Type: Short Survey

References (74)

1. Steen V.D., Mayes M.D., Merkel P.A. Assessment of kidney involvement. Clin Exp Rheumatol 2003, 21:S29-S31.
2. Cannon P.J., Hassar M., Case D.B., Casarella W.J., Sommers S.C., Leroy E.C. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 1974, 53:1-46.
3. Nishijima C., Sato S., Hasegawa M., Nagaoka T., Hirata A., Komatsu K., et al. Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology 2001, 40:406-409.
4. Rivolta R., Mascagni B., Berruti V., Quarto di P.F., Elli A., Scorza R., et al. Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy. Arthritis Rheum 1996, 39:1030-1034.
5. Scorza R., Rivolta R., Mascagni B., Berruti V., Bazzi S., Castagnone D., et al. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis. J Rheumatol 1997, 24:1944-1948.
6. Stone R.A., Tisher C.C., Hawkins H.K., Robinson R.R. Juxtaglomerular hyperplasia and hyperreninemia in progressive systemic sclerosis complicated acute renal failure. Am J Med 1974, 56:119-123.
7. Kovalchik M.T., Guggenheim S.J., Silverman M.H., Robertson J.S., Steigerwald J.C. The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 1978, 89:881-887.
8. Steen V.D., Medsger T.A., Osial T.A., Ziegler G.L., Shapiro A.P., Rodnan G.P. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984, 76:779-786.
9. Trostle D.C., Bedetti C.D., Steen V.D., al-Sabbagh M.R., Zee B., Medsger T.A. Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 1988, 31:393-400.
10. McWhorter J.E., Leroy E.C. Pericardial disease in scleroderma (systemic sclerosis). Am J Med 1974, 57:566-575.
11. Follansbee W.P. The cardiovascular manifestations of systemic sclerosis (scleroderma). Curr Probl Cardiol 1986, 11:241-298.
12. Karlen J.R., Cook W.A. Renal scleroderma and pregnancy. Obstet Gynecol 1974, 44:349-354.
13. Steen V.D., Conte C., Day N., Ramsey-Goldman R., Medsger T.A. Pregnancy in women with systemic sclerosis. Arthritis Rheum 1989, 32:151-157.
14. Montanelli G., Beretta L., Santaniello A., Scorza R. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 2013, 31:135-139.
15. Lam M., Ballou S.P. Reversible scleroderma renal crisis after cocaine use. N Engl J Med 1992, 326:1435.
16. Denton C.P., Sweny P., Abdulla A., Black C.M. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994, 33:90-92.
17. Nunokawa T., Akazawa M., Yokogawa N., Shimada K., Hiramatsu K., Nishio Y., et al. Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report. Am J Ther 2012, [Epub ahead of print]. 10.1097/MJT.0b013e3182583ba1.
18. Lunseth J.H., Baker L.A., Shifrin A. Chronic scleroderma with acute exacerbation during corticotropin therapy; report of a case with autopsy observations. AMA Arch Intern Med 1951, 88:783-792.
19. Sharnoff J.G., Carideo H.L., Stein I.D. Cortisone-treated scleroderma; report of a case with autopsy findings. J Am Med Assoc 1951, 145:1230-1232.
20. Helfrich D.J., Banner B., Steen V.D., Medsger T.A. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989, 32:1128-1134.
21. Steen V.D., Medsger T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998, 41:1613-1619.
22. Teixeira L., Mouthon L., Mahr A., Berezne A., Agard C., Mehrenberger M., et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50patients. Ann Rheum Dis 2008, 67:110-116.
23. Trang G., Steele R., Baron M., Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2012, 32:645-653.
24. Kobayashi H., Nishimaki T., Kaise S., Suzuki T., Watanabe K., Kasukawa R., et al. Immunohistological study endothelin-1and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 1999, 18:425-427.
25. Stratton R.J., Coghlan J.G., Pearson J.D., Burns A., Sweny P., Abraham D.J., et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM 1998, 91:561-566.
26. Mouthon L., Mehrenberger M., Teixeira L., Fakhouri F., Berezne A., Guillevin L., et al. Endothelin-1expression in scleroderma renal crisis. Hum Pathol 2011, 42:95-102.
27. Penn H., Quillinan N., Khan K., Chakravarty K., Ong V.H., Burns A., et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013, 106:839-848.
28. Fonseca C., Lindahl G.E., Ponticos M., Sestini P., Renzoni E.A., Holmes A.M., et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007, 357:1210-1220.
29. Wipff J., Gallier G., Dieude P., Avouac J., Tiev K., Hachulla E., et al. Angiotensin-converting enzyme gene does not contribute to genetic susceptibility to systemic sclerosis in European Caucasians. J Rheumatol 2009, 36:337-340.
30. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
31. Ghrenassia E., Avouac J., Khanna D., Derk C.T., Distler O., Atef S.Y., et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014, 41:99-105.
32. Shah A.A., Rosen A., Hummers L., Wigley F., Casciola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010, 62:2787-2795.
33. Batal I., Domsic R.T., Shafer A., Medsger T.A., Kiss L.P., Randhawa P., et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009, 40:332-340.
34. Penn H., Howie A.J., Kingdon E.J., Bunn C.C., Stratton R.J., Black C.M., et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007, 100:485-494.
35. Walker U.A., Tyndall A., Czirjak L., Denton C., Farge-Bancel D., Kowal-Bielecka O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
36. Steen V.D., Medsger T.A., Rodnan G.P. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982, 97:652-659.
37. Traub Y.M., Shapiro A.P., Rodnan G.P., Medsger T.A., McDonald R.H., Steen V.D., et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68cases. Medicine 1983, 62:335-352.
38. Steen V.D., Medsger T.A. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 1990, 16:1-10.
39. Donohoe J.F. Scleroderma and the kidney. Kidney Int 1992, 41:462-477.
40. Sugimoto T., Soumura M., Danno K., Kaji K., Kondo M., Hirata K., et al. Scleroderma renal crisis in a patient with anticentromere antibody-positive limited cutaneous systemic sclerosis. Mod Rheumatol 2006, 16:309-311.
41. Mandai S., Arai Y., Hirasawa S., Hirai T., Aki S., Inaba N., et al. Anti-centromere antibody-positive subjects presenting with hypertensive emergency and renal dysfunction in the absence of skin manifestations: a variant of systemic sclerosis or a novel entity?. Intern Med 2012, 51:1567-1572.
42. Steen V.D., Ziegler G.L., Rodnan G.P., Medsger T.A. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984, 27:125-131.
43. Korzets Z., Schneider M., Savin H., Ben-Chetrit S., Bernheim J., Shitrit P., et al. Intriguing presentation of scleroderma renal crisis (scleroderma renal crisis sine scleroderma sine hypertension). Nephrol Dial Transplant 1998, 13:2953-2956.
44. Molina J.F., Anaya J.M., Cabrera G.E., Hoffman E., Espinoza L.R. Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis. J Rheumatol 1995, 22:557-560.
45. Phan T.G., Cass A., Gillin A., Trew P., Fertig N., Sturgess A. Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis sine scleroderma. J Rheumatol 1999, 26:2489-2492.
46. Steen V.D., Medsger T.A. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 1997, 40:1146-1151.
47. Shanmugam V.K., Swistowski D.R., Saddic N., Wang H., Steen V.D. Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis. Clin Rheumatol 2011, 30:1363-1368.
48. Okano Y., Steen V.D., Medsger T.A. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993, 119:1005-1013.
49. Bunn C.C., Denton C.P., Shi-Wen X., Knight C., Black C.M. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998, 37:15-20.
50. Kuwana M., Pandey J.P., Silver R.M., Kawakami Y., Kaburaki J. HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. J Rheumatol 2003, 30:2392-2397.
51. Arnett F.C., Gourh P., Shete S., Ahn C.W., Honey R.E., Agarwal S.K., et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300Caucasian, African-American and Hispanic cases and 1000controls. Ann Rheum Dis 2010, 69:822-827.
52. Steen V.D., Syzd A., Johnson J.P., Greenberg A., Medsger T.A. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005, 32:649-655.
53. Clements P.J., Lachenbruch P.A., Furst D.E., Maxwell M., Danovitch G., Paulus H.E. Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. Arthritis Rheum 1994, 37:67-74.
54. Guillevin L., Berezne A., Seror R., Teixeira L., Pourrat J., Mahr A., et al. Scleroderma renal crisis: a retrospective multicentre study on 91patients and 427controls. Rheumatology 2012, 51:460-467.
55. Bar J., Ehrenfeld M., Rozenman J., Perelman M., Sidi Y., Gur H. Pulmonary-renal syndrome in systemic sclerosis. Semin Arthritis Rheum 2001, 30:403-410.
56. Yusin J., Lewin K., Clements P. Thrombotic thrombocytopenia purpura in a patient with systemic sclerosis. J Clin Rheumatol 2001, 7:106-111.
57. Kapur A., Ballou S.P., Renston J.P., Luna E., Chung-Park M. Recurrent acute scleroderma renal crisis complicated by thrombotic thrombocytopenic purpura. J Rheumatol 1997, 24:2469-2472.
58. Manadan A.M., Harris C., Block J.A. Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum 2005, 34:683-688.
59. Lian E.C. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13deficiency and beyond. Semin Thromb Hemost 2005, 31:625-632.
60. Gunduz O.H., Fertig N., Lucas M., Medsger T.A. Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. Arthritis Rheum 2001, 44:1663-1666.
61. Dimitroulas T., Sarafidis P., Roma V., Karagiannopoulou G., Kapoulas S., Dimitroula H., et al. Scleroderma renal crisis accompanied by new-onset pulmonary arterial hypertension: an acute systemic endothelial injury? Case report and literature. Inflamm Allergy Drug Targets 2010, 9:313-318.
62. Mitnick P.D., Feig P.U. Control of hypertension and reversal of renal failure in scleroderma. N Engl J Med 1978, 299:871-872.
63. Leroy E.C., Fleischmann R.M. The management of renal scleroderma: experience with dialysis, nephrectomy and transplantation. Am J Med 1978, 64:974-978.
64. Lopez-Ovejero J.A., Saal S.D., D'Angelo W.A., Cheigh J.S., Stenzel K.H., Laragh J.H. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979, 300:1417-1419.
65. Zawada E.T., Clements P.J., Furst D.A., Bloomer H.A., Paulus H.E., Maxwell M.H. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron 1981, 27:74-78.
66. Whitman H.H., Case D.B., Laragh J.H., Christian C.L., Botstein G., Maricq H., et al. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum 1982, 25:241-248.
67. Steen V.D., Costantino J.P., Shapiro A.P., Medsger T.A. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990, 113:352-357.
68. Pham P.T., Pham P.C., Danovitch G.M., Gritsch H.A., Singer J., Wallace W.D., et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 2005, 5:2565-2569.
69. Gibney E.M., Parikh C.R., Jani A., Fischer M.J., Collier D., Wiseman A.C. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant 2004, 4:2027-2031.
70. Caskey F.J., Thacker E.J., Johnston P.A., Barnes J.N. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 1997, 349:620.
71. Rajendran P.R., Molitor J.A. Resolution of hypertensive encephalopathy and scleroderma renal crisis with an angiotensin receptor blocker. J Clin Rheumatol 2005, 11:205-208.
72. Steen V.D., Medsger T.A. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000, 133:600-603.
73. Walker J.G., Ahern M.J., Smith M.D., Coleman M., Pile K., Rischmueller M., et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 2003, 33:216-220.
74. Hudson M. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis. Results from the International Scleroderma Renal Crisis Survey. Semin.Arthritis Rheum 2014, 43:666-672.